Your browser is no longer supported. Please, upgrade your browser.
Settings
CUR Neuralstem, Inc. daily Stock Chart
CUR [NASD]
Neuralstem, Inc.
Index- P/E- EPS (ttm)-0.21 Insider Own0.10% Shs Outstand11.40M Perf Week-12.39%
Market Cap43.55M Forward P/E- EPS next Y-2.34 Insider Trans- Shs Float10.67M Perf Month1093.75%
Income-20.40M PEG- EPS next Q-0.52 Inst Own8.70% Short Float57.29% Perf Quarter1264.29%
Sales0.01M P/S4354.80 EPS this Y11.50% Inst Trans-0.10% Short Ratio10.96 Perf Half Y1369.23%
Book/sh-0.03 P/B- EPS next Y5.30% ROA-174.40% Target Price29.25 Perf Year487.69%
Cash/sh0.50 P/C7.64 EPS next 5Y- ROE- 52W Range0.19 - 6.19 Perf YTD1314.81%
Dividend- P/FCF- EPS past 5Y11.50% ROI- 52W High-38.29% Beta1.65
Dividend %- Quick Ratio0.90 Sales past 5Y- Gross Margin- 52W Low1910.53% ATR0.47
Employees11 Current Ratio0.90 Sales Q/Q0.00% Oper. Margin- RSI (14)66.57 Volatility7.72% 13.40%
OptionableYes Debt/Eq- EPS Q/Q26.20% Profit Margin- Rel Volume0.18 Prev Close4.02
ShortableYes LT Debt/Eq- EarningsFeb 07 BMO Payout- Avg Volume558.05K Price3.82
Recom2.00 SMA2097.72% SMA50308.47% SMA200680.47% Volume99,250 Change-4.98%
Nov-07-16Initiated Aegis Capital Buy
Aug-29-16Initiated ROTH Capital Buy $1.20
Apr-28-15Initiated MLV & Co Buy $6
Feb-18-15Initiated Brean Capital Buy $8
Sep-08-14Initiated H.C. Wainwright Neutral
Jun-25-14Reiterated Aegis Capital Buy $6 → $7
Dec-10-12Reiterated Aegis Capital Buy $3 → $3.50
Aug-23-12Initiated Maxim Group Sell $0.25
Sep-22-11Initiated Morgan Joseph Buy $5
Jan-19-17 12:45PM  ETFs with exposure to Neuralstem, Inc. : January 19, 2017
Jan-12-17 09:30AM  Latest Reports on ImmunoCellular Therapeutics and Neuralstem as Biotech Industry Scrutiny Grows after President Trump's Comments Accesswire -6.24%
Jan-10-17 04:24PM  A Little Something for Everybody +59.06%
Jan-09-17 07:03AM  Splits Calendar: Neuralstem splits before market open today (1:13 ratio) +1,129.03%
Jan-06-17 05:11PM  NEURALSTEM, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, F
01:01PM  Neuralstem Announces a 1-for-13 Reverse Stock Split GlobeNewswire
Jan-04-17 10:52AM  ETFs with exposure to Neuralstem, Inc. : January 4, 2017
Dec-14-16 05:21PM  NEURALSTEM, INC. Files SEC form 8-K, Regulation FD Disclosure
Dec-12-16 07:41AM  NEURALSTEM, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Material Modification to Rights of Secur +12.50%
07:38AM  Neuralstem Announces the Closing of $20 Million Strategic Investment from Tianjin Pharmaceutical Group International Holdings Co., LTD. GlobeNewswire
Dec-08-16 02:31PM  ETFs with exposure to Neuralstem, Inc. : December 8, 2016 -7.69%
Nov-30-16 04:06PM  NEURALSTEM, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
Nov-28-16 12:02PM  ETFs with exposure to Neuralstem, Inc. : November 28, 2016
Nov-15-16 01:04PM  NEURALSTEM, INC. Financials +7.41%
Nov-14-16 01:10PM  ETFs with exposure to Neuralstem, Inc. : November 14, 2016
Nov-11-16 11:47AM  Neuralstem, Inc. :CUR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 11, 2016 +7.69%
Nov-08-16 04:48PM  NEURALSTEM, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
08:03AM  NEURALSTEM, INC. Files SEC form 10-Q, Quarterly Report
07:39AM  Neuralstem reports 3Q loss
07:35AM  Neuralstem Reports Third Quarter 2016 Results GlobeNewswire
Nov-07-16 09:37AM  Coverage initiated on Neuralstem by Aegis Capital +8.70%
Nov-02-16 07:35AM  Neuralstem Announces Presentations at Upcoming Scientific Conferences GlobeNewswire
Oct-27-16 01:21PM  ETFs with exposure to Neuralstem, Inc. : October 27, 2016 -10.71%
Oct-21-16 04:07PM  NEURALSTEM, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
Oct-20-16 04:06PM  NEURALSTEM, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +7.14%
07:52AM  Neuralstem Presents NSI-189 Preclinical Neurocognitive Benefits at the Radiation Research Society Annual Meeting GlobeNewswire
Oct-05-16 10:14AM  ETFs with exposure to Neuralstem, Inc. : October 5, 2016
Sep-21-16 04:02PM  NEURALSTEM, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:32AM  Neuralstem Achieves 50% Enrollment in NSI-189 Phase 2 Trial in Major Depressive Disorder GlobeNewswire
Sep-13-16 10:24AM  ETFs with exposure to Neuralstem, Inc. : September 13, 2016 -6.67%
Sep-12-16 02:06PM  NEURALSTEM, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +7.14%
08:32AM  Neuralstem Presented NSI-189 Preclinical Data in Type 1 and Type 2 Diabetes at the Annual Meeting of the Diabetic Neuropathy Study Group GlobeNewswire
08:03AM  Neuralstem Receives $20,000,000 Strategic Investment from Tianjin Pharmaceutical Group GlobeNewswire
Sep-01-16 01:20PM  NEURALSTEM, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Aug-30-16 11:05AM  ETFs with exposure to Neuralstem, Inc. : August 30, 2016 +11.11%
Aug-19-16 12:49PM  ETFs with exposure to Neuralstem, Inc. : August 19, 2016
Aug-18-16 10:29AM  Neuralstem, Inc. :CUR-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016
Aug-11-16 05:13PM  Neuralstem reports 2Q loss
04:07PM  NEURALSTEM, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Neuralstem Reports Second Quarter 2016 Results and Provides Business and Clinical Updates GlobeNewswire
Aug-09-16 04:37PM  NEURALSTEM, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; -8.00%
Jul-21-16 01:55PM  ETFs with exposure to Neuralstem, Inc. : July 21, 2016
Jul-18-16 09:15AM  Stocks Coverage on the Healthcare Sector for Biostar Pharma, GlobeImmune, Neuralstem, and GW Pharma
Jun-23-16 04:47PM  NEURALSTEM, INC. Files SEC form 8-K, Other Events
Jun-21-16 04:40PM  NEURALSTEM, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:15AM  Neuralstem Announces NSI-189 Shows Enhancement of Long-Term Potentiation In Vitro GlobeNewswire
Jun-20-16 04:27PM  NEURALSTEM, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders +6.67%
Jun-16-16 04:01PM  NEURALSTEM, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Off
Jun-13-16 05:08PM  NEURALSTEM, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:45AM  Neuralstem Announces New Chairman and Further Reorganization Plans GlobeNewswire
Jun-10-16 04:07PM  NEURALSTEM, INC. Files SEC form 8-K, Other Events
Jun-07-16 04:02PM  NEURALSTEM, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events
Jun-06-16 04:01PM  NEURALSTEM, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
May-26-16 11:11AM  These 5 Stocks Under $10 Are About to Soar Higher +5.88%
May-23-16 04:03PM  NEURALSTEM, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure
May-20-16 08:32AM  Neuralstem Announces Plan of Reorganization to Further Align Business with Strategic Intent PR Newswire
May-19-16 07:14PM  ETFs with exposure to Neuralstem, Inc. : May 19, 2016
May-18-16 01:26PM  Neuralstem, Inc. :CUR-US: Earnings Analysis: Q1, 2016 By the Numbers
May-13-16 04:48PM  NEURALSTEM, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securiti
May-12-16 04:54PM  Neuralstem to Raise $1.08 Million PR Newswire
04:26PM  NEURALSTEM, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statement
09:07AM  Neuralstem Announces First Patient Enrolled in Phase 2 Clinical Trial in Major Depressive Disorder PR Newswire
May-09-16 08:37AM  Neuralstem reports 1Q loss
08:05AM  Neuralstem Reports Fiscal First Quarter 2016 Results and Business Update PR Newswire
08:03AM  NEURALSTEM, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
May-04-16 06:07AM  NEURALSTEM, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial EDGAR Online
May-03-16 08:22AM  Neuralstem Prices Underwritten Public Offering of Securities PR Newswire -40.68%
May-02-16 04:01PM  Neuralstem Announces Proposed Public Offering of Securities PR Newswire
Apr-22-16 06:11AM  NEURALSTEM, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; EDGAR Online
Apr-21-16 05:28PM  Neuralstem Receives NASDAQ Notice of Bid Price Deficiency PR Newswire
Apr-13-16 06:13AM  NEURALSTEM, INC. Files SEC form 8-K, Other Events +7.25%
Mar-16-16 05:29PM  NEURALSTEM, INC. Files SEC form 8-K, Other Events -10.00%
Mar-14-16 04:21PM  Neuralstem reports 4Q loss
04:19PM  NEURALSTEM, INC. Files SEC form 8-K, Results of Operations and Financial Condition
04:03PM  Neuralstem Reports Fourth Quarter and Year End 2015 Fiscal Results and Business Update PR Newswire
01:25PM  NEURALSTEM, INC. Files SEC form 10-K, Annual Report
Mar-10-16 08:02AM  Neuralstem to Present at 28th Annual Roth Conference PR Newswire
Mar-04-16 04:08PM  NEURALSTEM, INC. Files SEC form 8-K, Other Events
Feb-19-16 02:20PM  NEURALSTEM, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities, Change in Directors or Principal Officer +17.65%
Feb-16-16 07:35AM  Neuralstem Appoints Richard Daly as President and Chief Executive Officer PR Newswire +17.39%
Jan-27-16 05:24PM  NEURALSTEM, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
09:27AM  Neuralstem Presented Cell Therapy Update At Phacilitate Cell & Gene Therapy World Conference at noodls
09:02AM  Neuralstem Presented Cell Therapy Update At Phacilitate Cell & Gene Therapy World Conference
Jan-20-16 08:45AM  3 Stocks Tackling Concussion Issues in Pro Athletes Accesswire
Jan-11-16 04:08PM  NEURALSTEM, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:32AM  Neuralstem's Preclinical Alzheimer's Disease Data Published In Stem Cells Translational Medicine PR Newswire
Jan-06-16 08:35AM  Neuralstem to Present at the Biotech Showcase 2016 Conference in San Francisco PR Newswire
Dec-22-15 09:49AM  Neuralstem, Inc. Earnings Analysis: Q3, 2015 By the Numbers
Dec-08-15 05:05PM  NEURALSTEM, INC. Files SEC form 8-K, Other Events
07:32AM  Data for Neuralstem's Novel NSI-189 Molecule in Major Depressive Disorder Published in Molecular Psychiatry PR Newswire
Nov-16-15 04:13PM  NEURALSTEM, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Byl
Nov-10-15 04:04PM  NEURALSTEM, INC. Files SEC form 8-K, Results of Operations and Financial Condition -7.44%
Nov-09-15 04:11PM  NEURALSTEM, INC. Files SEC form 10-Q, Quarterly Report
09:21AM  Neuralstem reports 3Q loss
09:03AM  Neuralstem Reports Third Quarter 2015 Financial Results PR Newswire
Oct-02-15 06:09AM  Biotech Stock Mailbag: Akebia, Neuralstem, Arrowhead at TheStreet
Sep-29-15 02:10PM  NEURALSTEM, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -12.66%
08:01AM  Neuralstem Investigator Provides Phase II Update on ALS Cell Therapy at American Neurological Association Annual Meeting PR Newswire
Sep-24-15 09:01AM  Neuralstem Investigator to Provide Update on ALS and Alzheimer's at American Neurological Association Annual Meeting PR Newswire +26.14%
Sep-23-15 09:59AM  Neuralstem, Inc. breached its 50 day moving average in a Bullish Manner : September 23, 2015
Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of central nervous system therapies based on its proprietary human neuronal stem cells and stem-cell derived small molecule compounds. The company's stem cell technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its clinical development products include NSI-189, which has completed Phase I clinical trial for the treatment of major depressive disorder, as well as is in Phase I clinical trial for the treatment of other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy; and NSI566 that has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. The company was founded in 1996 and is headquartered in Germantown, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Daly Richard JChief Executive OfficerDec 23Buy0.3132,25910,000134,939Dec 30 04:05 PM
Daly Richard JChief Executive OfficerNov 25Buy0.2835,71510,000102,680Nov 28 05:36 PM
Daly Richard JChief Executive OfficerOct 25Buy0.2835,71510,00066,965Oct 27 04:05 PM
Daly Richard JChief Executive OfficerSep 23Buy0.3231,25010,00031,250Sep 26 04:50 PM
LLOYD JONES JONATHAN BRIANChief Financial OfficerSep 23Buy0.3231,25010,00031,250Sep 26 04:51 PM
GARR RICHARDCEOJan 27Option Exercise0.0019,80201,456,269Jan 28 04:00 PM